Top Markets
#1 Brevis Brevis +37.75%
#2 Talus Network Talus Network +30.27%
#3 Tung Tung Tung Sahur Tung Tung Tung Sahur +30.12%
#4 Keep Network Keep Network +29.03%
#5 MemeCore MemeCore +24.60%
#6 Infinity Ground Infinity Ground +22.76%
#7 Allora Allora +20.35%
#8 Starpower Starpower +20.08%
#9 Synapse Synapse +18.93%
#10 屎壳郎 (Dung Beetle) 屎壳郎 (Dung Beetle) +18.73%
Coin of the day
Brevis Brevis
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
IntegraGen SA IntegraGen SA

IntegraGen SA

ALINT
Kedudukan dalam Saham #19673
IntegraGen SA provides human genome analysis services for academic researcher... IntegraGen SA provides human genome analysis services for academic researcher and life sciences companies in France. Its genomic services include transcriptomics, epigenomics, DNA sequencing, NGS testing for cancer research, and SNP genotyping. The company offers clinical research services, such as clinical grade sequencing and pharmacogenomics; basic and human genetic research; agrigenomic services, including crop and livestock genotyping and high-throughput sequencing for crops and livestock; and microbial genomics services comprising whole-genome microbial sequencing and microbial transcriptomics. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; SIRIUS, a cloud-based software tool that enables researchers to analyze whole genome, whole exome, and gene panel sequencing data; Galileo, a cloud-based app for dynamic exporation of RNA-Seq expression data; and GeCo, a genomic consulting service that offers researchers with access to biostatistics and bioanalytics experts. IntegraGen SA was founded in 2000 and is headquartered in Évry, France. IntegraGen SA is a subsidiary of OncoDNA SA.
Harga Saham
$0.20876331
Modal Pasaran
$1.38M
Perubahan (1 hari)
1.15%
Perubahan (1 tahun)
-64.84%
Negara
FR
Perdagangan IntegraGen SA (ALINT)

Kategori

Healthcare
Pendapatan untuk IntegraGen SA (ALINT)
Pendapatan pada Dec 2025 TTM: $-3.23M
Menurut laporan kewangan terkini IntegraGen SA, pendapatan semasa syarikat ialah $-3.23M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-286.40K, penurunan berbanding pendapatan pada tahun 2022 yang berjumlah $-153.95K. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi IntegraGen SA dari 2008 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-3.23M 782.69%
2024 $-366.28K 27.89%
2023 $-286.40K 86.04%
2022 $-153.95K 18.42%
2021 $-130.00K -77.17%
2020 $-569.29K 15.84%
2019 $-491.43K -67.91%
2018 $-1.53M 6.75%
2017 $-1.43M -29.04%
2016 $-2.02M 0.08%
2015 $-2.02M 10.76%
2014 $-1.82M -54.01%
2013 $-3.96M 29.95%
2012 $-3.05M -5.30%
2011 $-3.22M -31.40%
2010 $-4.70M -3.84%
2009 $-4.88M -6.08%
2008 $-5.20M 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$24.72B -764,615.67%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.17B -159,875.15%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.16B -159,602.96%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -66,218.92%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.66B -51,304.66%
NL